SCHEMBL17294237

SCHEMBL17294237

CC(=O)NC1CC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9807704 0.91 MTNR1A (0.42)
SCHEMBL4420636 0.82 MTNR1A (0.56)
SCHEMBL11275440 0.79 MTNR1A (0.49)
SCHEMBL31072091 0.79 BRD4 (0.41)
SCHEMBL2634531 0.77
SCHEMBL23857880 0.76 THRB (0.38)
SCHEMBL658632 0.76 MTNR1A (0.50)
SCHEMBL9807691 0.73 TLR4 (0.44)
SCHEMBL30595323 0.73 MTNR1A (0.77)
SCHEMBL1029693 0.73 MTNR1A (0.77)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148975-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-04-05 EP disclosed
CN-106536489-A Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2017-03-22 CN disclosed
EP-2499145-B1 SPIRO-OXINDOLE MDM2 ANTAGONISTS UNIV MICHIGAN (US) 2016-01-27 EP disclosed
WO-2015180612-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 WO disclosed